Indaptus Therapeutics (INDP) Competitors $0.94 +0.05 (+5.39%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INDP vs. LTRN, CALC, ELEV, VYNE, LEXX, LUMO, OCX, MRKR, DTIL, and OKYOShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Lantern Pharma (LTRN), CalciMedica (CALC), Elevation Oncology (ELEV), VYNE Therapeutics (VYNE), Lexaria Bioscience (LEXX), Lumos Pharma (LUMO), OncoCyte (OCX), Marker Therapeutics (MRKR), Precision BioSciences (DTIL), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Lantern Pharma CalciMedica Elevation Oncology VYNE Therapeutics Lexaria Bioscience Lumos Pharma OncoCyte Marker Therapeutics Precision BioSciences OKYO Pharma Indaptus Therapeutics (NASDAQ:INDP) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability. Which has more volatility and risk, INDP or LTRN? Indaptus Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Do institutionals and insiders hold more shares of INDP or LTRN? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor INDP or LTRN? Indaptus Therapeutics received 1 more outperform votes than Lantern Pharma when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 75.00% of users gave Lantern Pharma an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Lantern PharmaOutperform Votes1275.00% Underperform Votes425.00% Does the media prefer INDP or LTRN? In the previous week, Indaptus Therapeutics' average media sentiment score of 0.00 equaled Lantern Pharma'saverage media sentiment score. Company Overall Sentiment Indaptus Therapeutics Neutral Lantern Pharma Neutral Do analysts prefer INDP or LTRN? Indaptus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 806.18%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Indaptus Therapeutics is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is INDP or LTRN more profitable? Lantern Pharma's return on equity of -56.91% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Lantern Pharma N/A -56.91%-51.17% Which has stronger valuation and earnings, INDP or LTRN? Lantern Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.55Lantern PharmaN/AN/A-$15.96M-$1.78-1.76 SummaryIndaptus Therapeutics beats Lantern Pharma on 9 of the 13 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.57M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.5510.5990.0517.18Price / SalesN/A195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.655.094.784.78Net Income-$15.42M$151.83M$120.31M$225.60M7 Day Performance-6.20%-2.13%-1.92%-1.23%1 Month Performance-10.24%-3.10%11.50%3.36%1 Year Performance-49.56%11.54%30.59%16.60% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.868 of 5 stars$0.94+5.4%$8.50+806.2%-49.0%$9.57MN/A-0.556LTRNLantern PharmaN/A$3.56+3.5%N/A-19.1%$38.40MN/A-1.9420CALCCalciMedica2.9477 of 5 stars$2.81+2.9%$19.33+588.0%-10.1%$37.88MN/A-2.5330Positive NewsELEVElevation Oncology1.9868 of 5 stars$0.64+0.6%$7.20+1,025.0%+26.0%$37.84MN/A-0.7840Analyst ForecastVYNEVYNE Therapeutics2.6593 of 5 stars$2.56flat$6.88+168.6%-3.8%$37.76M$493,000.00-2.9830News CoverageLEXXLexaria Bioscience3.1487 of 5 stars$2.16-3.6%$11.00+409.3%+71.5%$37.70M$464,278.00-4.777LUMOLumos Pharma3.0946 of 5 stars$4.34flat$8.63+98.7%+44.2%$37.54M$2.21M-1.0130High Trading VolumeOCXOncoCyte3.2596 of 5 stars$2.22-4.3%$4.42+98.9%-22.1%$37.36M$1.50M0.00120Analyst ForecastGap DownMRKRMarker Therapeutics4.0361 of 5 stars$4.13+1.5%$19.00+360.0%-1.3%$36.84M$3.31M0.0060News CoveragePositive NewsDTILPrecision BioSciences4.4754 of 5 stars$4.74-12.9%$39.50+733.3%-56.3%$36.36M$75.10M80.33200Positive NewsHigh Trading VolumeOKYOOKYO Pharma1.5665 of 5 stars$1.04-1.9%$7.00+573.0%-39.1%$35.20MN/A0.007 Related Companies and Tools Related Companies LTRN Alternatives CALC Alternatives ELEV Alternatives VYNE Alternatives LEXX Alternatives LUMO Alternatives OCX Alternatives MRKR Alternatives DTIL Alternatives OKYO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INDP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts